Company profile
CrystecPharma
Crystec works with the global pharmaceutical and health care industry to solve drug particle formation, formulation and process challenges. Crystecs proprietary mSAS (modified Supercritical Anti-Solvent) drug delivery technology is enabled by a highly efficient, stable and fully scalable manufacturing process and is approved by regulatory authorities.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzUyNzM2NjYxOWFkaXF6a2N4
Published 19 Jun 2026 15:28
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzMjMzNDE2OGFkaXF6a2N4 | Paper/PDF filed
Published 22 Aug 2024 07:06
Company registered at Companies House
1 Apr 2017 to 31 Mar 2020
This project focuses on cost effective health care provision for debilitating respiratory diseases, and especially chronic obstructive pulmonary disease (COPD). COPD currently affects 1 in 12 of the Chinese population over 40. Frequently patients respond poorly to current treatment due to drug resistance. Our innovative approach will overcome this issue w...
1 May 2016 to 31 Aug 2016
Crystec propose a re-purposed therapy for the treatment of Raynaud's Phenomenon.
1 Sep 2012 to 28 Feb 2014
CrystecPharma is a crystal and particle engineering company enabling the development of new and more effective medicines. CrystecPharma applies the latest supercritical fluid (SCF) technology to create drug particles which dissolve more quickly and can be delivered via alternative routes of administration. Although a relatively young company the team have...
